Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Updated results.

被引：3
|
作者：
Makker, Vicky
Rasco, Drew W.
Vogelzang, Nicholas J.
Messing, Mark
Brose, Marcia S.
Cohn, Allen Lee
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5596
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China
    Liao, Xiaodong
    Wu, Yajing
    Lin, Dong
    Gu, Dian
    Luo, Shaohong
    Huang, Xiaoting
    Xu, Xiongwei
    Weng, Xiuhua
    Lin, Shen
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (05) : 881 - 889
  • [32] Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
    Lorusso, Domenica
    Danesi, Romano
    Locati, Laura Deborah
    Masi, Gianluca
    De Giorgi, Ugo
    Gadducci, Angiolo
    Pignata, Sandro
    Roberto, Sabbatini
    Savarese, Antonella
    Valabrega, Giorgio
    Zamagni, Claudio
    Colombo, Nicoletta
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma
    Makker, Vicky
    Cohen, Allen
    Taylor, Matthew
    Minoshima, Yukinori
    Kato, Yu
    Dairiki, Ryo
    Kanekiyo, Michio
    Yachie, Ayako
    Kodama, Kotaro
    Sachdev, Pallavi
    Matsui, Junji
    Funahasi, Yasuhiro
    Young, Louise
    Rasco, Drew
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 175 - 176
  • [34] Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden
    Ralph, Lewis
    Young, Kate
    Upadhyay, Navneet
    Prabhu, Vimalanand Shrikant
    Ljungcrantz, Christina
    Massaad, Rachid
    Xu, Ruifeng
    Giertz, Anna
    Merchant, Adil
    Orlowski, Robert
    Duska, Linda
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 483 - 491
  • [35] Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis
    Tochigi, Mikako
    Shigeta, Shogo
    Shimada, Muneaki
    Miyahara, Shuko
    Hasegawa-Minato, Junko
    Shibuya, Yusuke
    Ishibashi, Masumi
    Hashimoto, Chiaki
    Tokunaga, Hideki
    Yaegashi, Nobuo
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 262 (02): : 85 - 95
  • [36] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    Di Simone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett V.
    Orlowski, Robert
    McKenzie, Jodi A.
    Gillis, Kathryn
    Young, Louise
    Herraez, Antonio Casado
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 134
  • [37] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Lee Cohn, Allen
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett, V
    Orlowski, Robert
    Alicia McKenzie, Jodi
    Gillis, Kathryn
    Casado Herraez, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
    Fujii, H.
    Nishikawa, T.
    Yoshida, H.
    Ozawa, R.
    Hoshino, M.
    Saito, A.
    Ito, M.
    Kita, S.
    Maejima, A.
    Kojima, Y.
    Sudo, K.
    Shimoi, T.
    Yonemori, K.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1592 - S1593
  • [39] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [40] Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro D.
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    Mccormack, Mary
    Massaad, Rachid
    Nguyen, Allison Martin
    Zhao, Qi
    Mckenzie, Jodi
    Prabhu, Vimalanand S.
    Makker, Vicky
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 186 : 172 - 184
12345